The drug discovery incubator project in collaboration with leading domestic and international institutions, led and promoted by Bloom X³ Co.Ltd. (Headquarters: Tokyo, CEO: Hiromichi Kimura), has been selected for the JETRO Subsidy Program for Promoting Foreign Direct Investment in Japan.
JETRO (Japan External Trade Organization) is an independent administrative agency under the Ministry of Economy, Trade and Industry (METI) of Japan. It plays a central role in facilitating foreign direct investment into Japan and promoting international business collaboration. Within this framework, the subsidy program is highly selective, with only a limited number of projects approved after rigorous screening.
The official title of the selected project is:
“Transformative BNCT (Boron Neutron Capture Therapy) Platform Development: Refractory Cancers, Rejuvenation, and Regenerative Medicine.”
This initiative aims to develop a BNCT-based transformative platform that opens new horizons in refractory cancer treatment, rejuvenation medicine, and regenerative therapies.
Going forward, Bloom X³（Former The Global Blooming） will continue to collaborate proactively with top-tier partners worldwide, accelerating efforts from multiple dimensions to bring innovative therapies into real-world practice. By integrating research, investment, and international collaboration, we aim to steadily advance the creation of transformative medical solutions for the future.
Reference Link
JETRO Announcement
日本語版はこちら: 世界に挑む新しい治療法──Bloom X³（旧The Global Blooming)の創薬インキュベータープロジェクトがJETRO補助金に採択
